# A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

> **NCT00513565** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 22 (actual)

## Conditions studied

- Depressive Disorder and Anxiety Disorders

## Interventions

- **DRUG:** single dose

## Key facts

- **NCT ID:** NCT00513565
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-13
- **Primary completion:** 2009-05-14
- **Final completion:** 2009-05-14
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513565, "A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00513565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*